0001104659-17-073391.txt : 20180313 0001104659-17-073391.hdr.sgml : 20180313 20171214171603 ACCESSION NUMBER: 0001104659-17-073391 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20171214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0000792977 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042742593 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 6174983300 MAIL ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MAGNETICS INC DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm

 

December 14, 2017

 

Via EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Mail Stop 4546

Washington, D.C. 20549

Attn: Jim B. Rosenberg, Mark Brunhofer and Sharon Blume, Office of Healthcare & Insurance

 

Re:                      AMAG Pharmaceuticals, Inc.

Form 10-K for the Fiscal Year Ended December 31, 2016

Filed February 21, 2017

Form 10-Q for the Quarterly Period Ended September 30, 2017

Filed November 6, 2017

File No. 001-10865

 

Dear Mr. Rosenberg, Mr. Brunhofer and Ms. Blume:

 

On behalf of AMAG Pharmaceuticals, Inc. (the “Company”), the Company hereby advises the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) that the Company has received the Staff’s letter dated December 13, 2017 (the “Comment Letter”), regarding the Commission’s review of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2017.  The Company respectfully requests an extension until January 12, 2018 to respond to the Comment Letter in order to provide sufficient time for the Company to prepare the response.  The Company is committed to responding to the Comment Letter promptly and intends to provide a response to the Staff no later than January 12, 2018.  Should you have any questions regarding the request made herein, please do not hesitate to contact me at (617) 570-1762.  Thank you very much for your courtesy and cooperation in this matter.

 

 

Sincerely,

 

 

 

/s/ Jacqueline Mercier

 

Jacqueline Mercier, Esq.

 

Goodwin Procter LLP

 

cc:                                Edward Myles, AMAG Pharmaceuticals, Inc.

Joseph D. Vittiglio, AMAG Pharmaceuticals, Inc.

Ettore A. Santucci, Goodwin Procter LLP